Cytori provides regenerative medicine devices and cell therapy. Their Celution system extracts stem and regenerative cells from fatty tissue for soft tissue repair and cardiovascular disease applications. Recent highlights include expanded approval in Europe and initiating a heart attack trial in 2011. Cytori has a strong balance sheet with $60 million in cash and is pursuing near-term revenue growth from soft tissue applications while developing cardiovascular indications.
Cytori Therapeutics presented at the Lazard Capital Markets 8th Annual Healthcare Conference. They discussed their large pipeline opportunities including EU chronic ischemia approval and US chronic ischemia pilot trial. They also highlighted the near term commercial potential of their soft tissue and translational research, growing in select emerging markets. Cytori has established partnerships that have provided over $100 million in funding and sees potential future licensing opportunities. Their patent protection extends into the mid-2020s.
New York City Health & Hospitals Corporationlponssa
This document summarizes the transformation of the supply chain management at NYC Health and Hospitals Corporation (HHC). HHC is the largest municipal healthcare system in the US, serving 1.3 million patients annually. It was facing a $1 billion budget shortfall and needed to restructure its supply chain to reduce costs. The transformation established pillars like strategic sourcing, vendor management, and performance management to standardize processes and leverage the system's size. The results included over $8 million in supply savings in the first year and a projected $21.46 million in total annual savings from various initiatives. Key metrics were also implemented to track progress. The transformation of the supply chain was a critical part of HHC's "Road A
The document describes the T17 high-performing battery rider scrubber. It highlights key features such as large battery capacity for extended runtime, durable construction to withstand harsh environments, and ec-H2O technology for effective cleaning. The scrubber aims to reduce cleaning costs through productivity and durability while also improving safety and facility image. It provides easy operation and maintenance through features like intuitive controls and yellow touch points. Optional configurations allow customization to meet different customer needs.
Croco Toyota is offering this vehicle among other brands including but not limited to Ford Ranger T6 (double and single cabs), Nisaan NP300, Kia sedans and SUVs, Landrover and Jaguar through our Premier Auto Division. We are proud to offer you all vehicles according to your taste, wallet and usage!
- Indian stock benchmarks settled flat after volatile trading, with the Nifty ending slightly higher, as markets took support from gains in global markets but saw no domestic catalysts.
- Key sectors like IT and real estate gained while metals and consumer durables declined.
- Several companies like Tata Power and HDFC Bank rose while Coal India and ONGC fell.
El documento describe una conferencia de un candidato escolar llamado Hazael Contreras del partido blanco. Hazael propone becas de comida para estudiantes de bajos recursos y un pase automático a la universidad para estudiantes con promedios de 10, 9 o 8.6. Los estudiantes elogian las propuestas de Hazael y dicen que él se preocupa por su bienestar, a diferencia de otros candidatos. Hazael promete escuchar las peticiones de los estudiantes para crear un mejor futuro. El público aplaude y vota
Cytori Therapeutics presented at the Lazard Capital Markets 8th Annual Healthcare Conference. They discussed their large pipeline opportunities including EU chronic ischemia approval and US chronic ischemia pilot trial. They also highlighted the near term commercial potential of their soft tissue and translational research, growing in select emerging markets. Cytori has established partnerships that have provided over $100 million in funding and sees potential future licensing opportunities. Their patent protection extends into the mid-2020s.
New York City Health & Hospitals Corporationlponssa
This document summarizes the transformation of the supply chain management at NYC Health and Hospitals Corporation (HHC). HHC is the largest municipal healthcare system in the US, serving 1.3 million patients annually. It was facing a $1 billion budget shortfall and needed to restructure its supply chain to reduce costs. The transformation established pillars like strategic sourcing, vendor management, and performance management to standardize processes and leverage the system's size. The results included over $8 million in supply savings in the first year and a projected $21.46 million in total annual savings from various initiatives. Key metrics were also implemented to track progress. The transformation of the supply chain was a critical part of HHC's "Road A
The document describes the T17 high-performing battery rider scrubber. It highlights key features such as large battery capacity for extended runtime, durable construction to withstand harsh environments, and ec-H2O technology for effective cleaning. The scrubber aims to reduce cleaning costs through productivity and durability while also improving safety and facility image. It provides easy operation and maintenance through features like intuitive controls and yellow touch points. Optional configurations allow customization to meet different customer needs.
Croco Toyota is offering this vehicle among other brands including but not limited to Ford Ranger T6 (double and single cabs), Nisaan NP300, Kia sedans and SUVs, Landrover and Jaguar through our Premier Auto Division. We are proud to offer you all vehicles according to your taste, wallet and usage!
- Indian stock benchmarks settled flat after volatile trading, with the Nifty ending slightly higher, as markets took support from gains in global markets but saw no domestic catalysts.
- Key sectors like IT and real estate gained while metals and consumer durables declined.
- Several companies like Tata Power and HDFC Bank rose while Coal India and ONGC fell.
El documento describe una conferencia de un candidato escolar llamado Hazael Contreras del partido blanco. Hazael propone becas de comida para estudiantes de bajos recursos y un pase automático a la universidad para estudiantes con promedios de 10, 9 o 8.6. Los estudiantes elogian las propuestas de Hazael y dicen que él se preocupa por su bienestar, a diferencia de otros candidatos. Hazael promete escuchar las peticiones de los estudiantes para crear un mejor futuro. El público aplaude y vota
Este documento discute varios temas relacionados con la privacidad en Internet. Explica el derecho a la privacidad y cómo la información personal que las personas publican en línea y comparten a través de las redes sociales y otras plataformas plantea amenazas a la privacidad. También analiza las herramientas que usan las empresas para recopilar datos personales de los usuarios y crear perfiles de comportamiento, y los efectos que esto tiene en la privacidad individual. Además, presenta algunas soluciones tecnológicas para mejorar la
Jorge Adrian Carvajal Guerra se postula para la presidencia del colegio de bachilleres con propuestas como respeto entre estudiantes, maestros y personal; instalaciones seguras y limpias; salir a la hora indicada en el horario; y equipos nuevos en las salas de cómputo. Su campaña promueve la armonía y el respeto mutuo a través de un video con estudiantes y maestros que piden un plantel mejor, con el eslogan "¡Carvajal Puede Asegurar!".
Este documento presenta la planificación de un proyecto escolar de arte dramático llamado "Teatro y Drama sin Fronteras". El proyecto busca que los estudiantes conozcan, comprendan y respeten la diversidad cultural a través del arte dramático para fomentar la convivencia y el desarrollo personal. El proyecto se implementará durante el año escolar a través de actividades como juego dramático, títeres, sociodrama, pantomima y payasadas.
Este documento ofrece una variedad de opciones de entretenimiento para bodas, incluyendo música en vivo (bandas, DJ), baile tradicional, exhibiciones de cetrería, y servicios de belleza para novias.
There are three main types of diabetes: type 1, type 2, and gestational diabetes. Type 1 diabetes occurs when the body does not produce insulin and affects approximately 10% of diabetes cases. Type 2 diabetes occurs when the body does not produce enough insulin or the cells do not respond to insulin properly and accounts for around 90% of diabetes cases worldwide. Gestational diabetes develops in females during pregnancy and while most cases can be managed with diet and exercise, 10-20% may require medication to control blood glucose levels.
This document discusses institutions and institutional theory. It begins by outlining the significance of institutions and how they matter for economic development. It then defines institutions and lists some of their key characteristics, including structure, stability, regulating behavior, and shared values. The document also presents a typology of institutional theories, including historical institutionalism, rational choice institutionalism, and normative institutionalism. It provides details on historical institutionalism and how institutions evolve over time through path dependence.
CYTX 6th International Conference on Cell Therapy for Cardiovascular Disease ...Cytori Therapeutics, Inc.
Presented by Brad Conlan, Director of Regenerative Medicine on Thursday, January 20 at a Product Development Panel at the 6th International Conference on Cell Therapy for Cardiovascular Disease
This document provides an overview of Bio Master and discusses the importance of adult stem cell research, applications of adipose-derived stem cells, and the necessity of technological development in stem cell isolation. It notes that adult stem cells can be easily obtained from fat tissues in large quantities and utilized for patient-specific therapies. Current trends in stem cell extractors are also examined, with some companies highlighted that have retained technologies for stem cell extraction methods and systems.
Cytori Therapeutics is a leader in cell therapy with 57 issued patents and 75 pending. Their Celution device is approved in the EU for tissue ischemia and wounds. The company is conducting a US trial called ATHENA to assess the safety and feasibility of using adipose-derived regenerative cells to treat refractory heart failure. Cytori is also partnering with BARDA to develop their next generation Celution system and conduct proof-of-concept studies for burn treatments. Cytori aims to accelerate revenue growth and achieve profitability through expanding commercial sales and translational medicine programs.
This document summarizes a presentation made by Fibrocell Science at the UBS Global Life Sciences Conference on September 20, 2011. The presentation outlines Fibrocell Science's vision to be a unique autologous cellular therapeutic company focused on aesthetics and dermatology. Specifically, it discusses laViv, an innovative autologous fibroblast technology to treat wrinkles and folds, as well as potential applications for restrictive burn scars, vocal cord scarring, and other indications. The presentation highlights the growing aesthetics market, laViv's patient and physician value propositions, clinical trial results demonstrating improvement in skin quality characteristics, and photos showcasing laViv's effects on nasolabial folds.
Fibrocell Science, Inc. (OTCBB: FCSC) is a cell therapy company focused on the development of a line of autologous tissue regeneration products for aesthetic, medical, and scientific applications. Using Fibrocell Science's patented process, a patient’s own fibroblast cells are harvested using a minimally invasive skin procedure, then processed, multiplied, purified, cryopreserved and re-injected as personalized therapy. Fibroblasts are cells that contribute to the production of collagen essential in the formation of connective tissue fibers. These matrix fibers are critical to the strength and elasticity of the skin.
This document provides an overview of Cytori Therapeutics and its cell therapy technology. It discusses Cytori's proprietary process for deriving stem and regenerative cells from a patient's own adipose tissue. It highlights clinical trial results showing benefits of the therapy for heart failure patients. The document also outlines Cytori's business partnerships, including a contract with BARDA to develop the therapy for burns, and revenue opportunities in both international markets and translational research applications. Key milestones for 2013 include completing enrollment in a heart failure trial and advancing the BARDA contract.
Fibrocell Science is a regenerative medicine company focused on developing autologous cell therapies using a patient's own fibroblast cells. Their lead product, LAVIV, is the first FDA-approved cell-based therapy for treating nasolabial folds and has shown encouraging results in clinical studies. Fibrocell has additional programs in development for indications like acne scarring, burn scars, and vocal cord scarring. The company is working to expand their fibroblast platform to new areas of aesthetic dermatology and regenerative medicine through additional clinical trials and development projects.
The document provides information about adipose-derived stem cells (ADSCs) and their clinical applications. It discusses that ADSCs can be easily harvested from fat using liposuction, cultured to increase cell numbers, and stored for future use. The document describes the multi-station system, which allows for harvesting fat, extracting ADSCs, and re-infusing the cells back into the patient in a single day in the operating room. It provides a step-by-step protocol for isolating ADSCs from fat tissue using the multi-station system involving liposuction, collagenase digestion, centrifugation, and washing steps. Potential clinical applications discussed include wound healing and breast reconstruction procedures.
Lattice Biologics develops and manufactures biologic products to domestic and international markets. Lattice’s products are used in a variety of applications, including:
- Enhancing fusion in spine surgery
- Enhancing breast reconstruction post mastectomy for breast cancer patients
- Sports medicine indications, including ACL repair
- Promotion of bone regeneration in foot and ankle surgery
- Promotion of skull healing following neurosurgery
- Enhancing wound repair in burn victims
- Subchondral bone defect repair in knee and other joint surgeries
Cytori Therapeutics presented at the Meeting on the Mesa conference on October 29, 2012. The presentation highlighted Cytori's (1) scientific leadership in characterizing adipose-derived regenerative cells, (2) $106 million contract from BARDA to develop cell therapy for thermal burns, and (3) extensive patent portfolio protecting its Celution technology through the mid-2020s.
The value proposition document discusses examples of value propositions in the Lean LaunchPad presentation, including proposing sustainable replacements for petroleum-derived feedstocks and a solution for labor-intensive hand weed control. It also outlines CanScan's value proposition as a cell culture company that can uniquely isolate, count, analyze, and culture circulating tumor cells to characterize cancer aggressiveness and test chemotherapies.
Este documento discute varios temas relacionados con la privacidad en Internet. Explica el derecho a la privacidad y cómo la información personal que las personas publican en línea y comparten a través de las redes sociales y otras plataformas plantea amenazas a la privacidad. También analiza las herramientas que usan las empresas para recopilar datos personales de los usuarios y crear perfiles de comportamiento, y los efectos que esto tiene en la privacidad individual. Además, presenta algunas soluciones tecnológicas para mejorar la
Jorge Adrian Carvajal Guerra se postula para la presidencia del colegio de bachilleres con propuestas como respeto entre estudiantes, maestros y personal; instalaciones seguras y limpias; salir a la hora indicada en el horario; y equipos nuevos en las salas de cómputo. Su campaña promueve la armonía y el respeto mutuo a través de un video con estudiantes y maestros que piden un plantel mejor, con el eslogan "¡Carvajal Puede Asegurar!".
Este documento presenta la planificación de un proyecto escolar de arte dramático llamado "Teatro y Drama sin Fronteras". El proyecto busca que los estudiantes conozcan, comprendan y respeten la diversidad cultural a través del arte dramático para fomentar la convivencia y el desarrollo personal. El proyecto se implementará durante el año escolar a través de actividades como juego dramático, títeres, sociodrama, pantomima y payasadas.
Este documento ofrece una variedad de opciones de entretenimiento para bodas, incluyendo música en vivo (bandas, DJ), baile tradicional, exhibiciones de cetrería, y servicios de belleza para novias.
There are three main types of diabetes: type 1, type 2, and gestational diabetes. Type 1 diabetes occurs when the body does not produce insulin and affects approximately 10% of diabetes cases. Type 2 diabetes occurs when the body does not produce enough insulin or the cells do not respond to insulin properly and accounts for around 90% of diabetes cases worldwide. Gestational diabetes develops in females during pregnancy and while most cases can be managed with diet and exercise, 10-20% may require medication to control blood glucose levels.
This document discusses institutions and institutional theory. It begins by outlining the significance of institutions and how they matter for economic development. It then defines institutions and lists some of their key characteristics, including structure, stability, regulating behavior, and shared values. The document also presents a typology of institutional theories, including historical institutionalism, rational choice institutionalism, and normative institutionalism. It provides details on historical institutionalism and how institutions evolve over time through path dependence.
CYTX 6th International Conference on Cell Therapy for Cardiovascular Disease ...Cytori Therapeutics, Inc.
Presented by Brad Conlan, Director of Regenerative Medicine on Thursday, January 20 at a Product Development Panel at the 6th International Conference on Cell Therapy for Cardiovascular Disease
This document provides an overview of Bio Master and discusses the importance of adult stem cell research, applications of adipose-derived stem cells, and the necessity of technological development in stem cell isolation. It notes that adult stem cells can be easily obtained from fat tissues in large quantities and utilized for patient-specific therapies. Current trends in stem cell extractors are also examined, with some companies highlighted that have retained technologies for stem cell extraction methods and systems.
Cytori Therapeutics is a leader in cell therapy with 57 issued patents and 75 pending. Their Celution device is approved in the EU for tissue ischemia and wounds. The company is conducting a US trial called ATHENA to assess the safety and feasibility of using adipose-derived regenerative cells to treat refractory heart failure. Cytori is also partnering with BARDA to develop their next generation Celution system and conduct proof-of-concept studies for burn treatments. Cytori aims to accelerate revenue growth and achieve profitability through expanding commercial sales and translational medicine programs.
This document summarizes a presentation made by Fibrocell Science at the UBS Global Life Sciences Conference on September 20, 2011. The presentation outlines Fibrocell Science's vision to be a unique autologous cellular therapeutic company focused on aesthetics and dermatology. Specifically, it discusses laViv, an innovative autologous fibroblast technology to treat wrinkles and folds, as well as potential applications for restrictive burn scars, vocal cord scarring, and other indications. The presentation highlights the growing aesthetics market, laViv's patient and physician value propositions, clinical trial results demonstrating improvement in skin quality characteristics, and photos showcasing laViv's effects on nasolabial folds.
Fibrocell Science, Inc. (OTCBB: FCSC) is a cell therapy company focused on the development of a line of autologous tissue regeneration products for aesthetic, medical, and scientific applications. Using Fibrocell Science's patented process, a patient’s own fibroblast cells are harvested using a minimally invasive skin procedure, then processed, multiplied, purified, cryopreserved and re-injected as personalized therapy. Fibroblasts are cells that contribute to the production of collagen essential in the formation of connective tissue fibers. These matrix fibers are critical to the strength and elasticity of the skin.
This document provides an overview of Cytori Therapeutics and its cell therapy technology. It discusses Cytori's proprietary process for deriving stem and regenerative cells from a patient's own adipose tissue. It highlights clinical trial results showing benefits of the therapy for heart failure patients. The document also outlines Cytori's business partnerships, including a contract with BARDA to develop the therapy for burns, and revenue opportunities in both international markets and translational research applications. Key milestones for 2013 include completing enrollment in a heart failure trial and advancing the BARDA contract.
Fibrocell Science is a regenerative medicine company focused on developing autologous cell therapies using a patient's own fibroblast cells. Their lead product, LAVIV, is the first FDA-approved cell-based therapy for treating nasolabial folds and has shown encouraging results in clinical studies. Fibrocell has additional programs in development for indications like acne scarring, burn scars, and vocal cord scarring. The company is working to expand their fibroblast platform to new areas of aesthetic dermatology and regenerative medicine through additional clinical trials and development projects.
The document provides information about adipose-derived stem cells (ADSCs) and their clinical applications. It discusses that ADSCs can be easily harvested from fat using liposuction, cultured to increase cell numbers, and stored for future use. The document describes the multi-station system, which allows for harvesting fat, extracting ADSCs, and re-infusing the cells back into the patient in a single day in the operating room. It provides a step-by-step protocol for isolating ADSCs from fat tissue using the multi-station system involving liposuction, collagenase digestion, centrifugation, and washing steps. Potential clinical applications discussed include wound healing and breast reconstruction procedures.
Lattice Biologics develops and manufactures biologic products to domestic and international markets. Lattice’s products are used in a variety of applications, including:
- Enhancing fusion in spine surgery
- Enhancing breast reconstruction post mastectomy for breast cancer patients
- Sports medicine indications, including ACL repair
- Promotion of bone regeneration in foot and ankle surgery
- Promotion of skull healing following neurosurgery
- Enhancing wound repair in burn victims
- Subchondral bone defect repair in knee and other joint surgeries
Cytori Therapeutics presented at the Meeting on the Mesa conference on October 29, 2012. The presentation highlighted Cytori's (1) scientific leadership in characterizing adipose-derived regenerative cells, (2) $106 million contract from BARDA to develop cell therapy for thermal burns, and (3) extensive patent portfolio protecting its Celution technology through the mid-2020s.
The value proposition document discusses examples of value propositions in the Lean LaunchPad presentation, including proposing sustainable replacements for petroleum-derived feedstocks and a solution for labor-intensive hand weed control. It also outlines CanScan's value proposition as a cell culture company that can uniquely isolate, count, analyze, and culture circulating tumor cells to characterize cancer aggressiveness and test chemotherapies.
-often suffer from cartilage injuries. Cartilage surgery is available in India to cure cartilage problems and prevent them from developing knee osteoarthritis. Autologous cartilage cell implantation is being done by Madras Joint replacement center at an affordable cost. This biological intervention will hopefully avoid a knee replacement in young individuals.
The document discusses BioTime, Inc., a biotechnology company leading the regenerative medicine revolution. It summarizes BioTime's expertise in pluripotent stem cells and its focus on advancing two clinical programs - Renevia for facial aesthetics and OpRegen for dry age-related macular degeneration. It outlines upcoming milestones for these programs in 2016-2017, and how BioTime is unlocking value from its ownership stakes in public subsidiaries Asterias and OncoCyte, which are applying BioTime's stem cell technologies to therapies for conditions with high unmet medical need.
John Ludlow presented on regenerative medicine past, present, and future. He discussed early work in organ transplantation and tissue engineering. Currently, there are over 50 companies developing regenerative medicine products and the field is starting to provide commercialized solutions. However, the path has not been straightforward. Moving forward, success may come from focusing on clinical and commercial viability, strategic intellectual property management, and iterative technology evolution driven by clinical needs. The future of regenerative medicine may include more personalized and rapid regenerative options.
The document provides information about a dental implant solutions company. It summarizes their comprehensive treatment, education, and business support solutions. Their treatment solutions include patient-driven implant systems, end-to-end prosthetic options, and site-specific regenerative materials. They offer an extensive educational continuum and business tools to help dental practices succeed.
American CryoStem Corporation was founded in 2008 to standardize adipose tissue-derived stem cell technologies. It operates FDA-registered clinical laboratories in New Jersey, Hong Kong, and Japan. The company leverages its intellectual property portfolio and clinical platform to create a global network of licensed laboratories, physicians, patients, and researchers. Its products include adult stem cells derived from adipose tissue and characterized for regenerative medicine applications. The company focuses on collaborations to discover, develop, and commercialize new adipose-derived stem cell products and applications.
American CryoStem Corporation was founded in 2008 to standardize adipose tissue-derived stem cell technologies. It operates FDA-registered clinical laboratories in New Jersey, Hong Kong, and Japan. The company leverages its intellectual property portfolio and stem cell products to create a global network of licensed laboratories, physicians, patients, and researchers. Its research focuses on collaborations to discover, develop, and commercialize adipose-derived stem cell products and applications in regenerative medicine.
American CryoStem Corporation is a biotechnology company founded in 2008 that operates FDA-registered clinical laboratories. It has developed a proprietary platform and portfolio of intellectual property focused on collecting, processing, storing, and differentiating adipose tissue and adipose-derived stem cells for regenerative medicine applications. The company's products and services are aimed at allowing individuals to prepare for their current or future regenerative medicine needs by storing their stem cells when they are young and healthy.
Cytori Therapeutics is presenting at the 26th Annual Roth Conference. They provide an overview of their adipose-derived cell therapy technology and development pipeline. Their focus is on cardiovascular disease and soft tissue injuries. Key highlights include their ongoing Phase II U.S. heart failure trial, a U.S. government contract for up to $106 million to develop treatment for thermal burns, and a pipeline supported by independent clinical studies of additional indications. They discuss their commercial model of selling proprietary cell therapy devices and single-use consumables, as well as progress on strategic partnerships.
Cytori Corporate Overview provides an overview of Cytori Therapeutics, Inc., a company that develops cell therapy technology. The summary includes:
1) Cytori has a transformative cell therapy platform that is regulated as a device and uses a business model of single-use consumables.
2) The technology has clinical experience in thousands of patients and strong intellectual property protection.
3) Near-term value drivers include milestones from a U.S. government contract, upcoming cardiovascular trial data, and international approvals and revenue growth.
Cytori Therapeutics is developing adipose-derived regenerative cell therapies using a point-of-care device platform. The platform allows for autologous cell therapies to be prepared at the bedside from a patient's own fat tissue. Clinical trials show the cells are safe and may provide benefits in cardiac and soft tissue applications. Near-term value drivers include government contract milestones and cardiovascular trial data. The business model involves selling single-use consumables for each procedure at price points around $2,000-$12,000, depending on the indication.
Cytori Therapeutics is a biotechnology company focused on developing cell therapies using adipose-derived regenerative cells (ADRCs). Their Celution system processes adipose tissue to isolate and concentrate a mixed population of ADRCs. Key priorities include completing cardiac clinical trials to treat heart failure and leveraging their platform through partnerships with BARDA and commercial sales of their system. Upcoming milestones are achieving objectives under the BARDA contract, reporting results from their US ATHENA heart failure trial, and publishing longer term data from their European cardiac trial.
Cytori Corporate Overview provides the following information in 3 sentences:
Cytori has a transformative cell therapy technology platform using adipose-derived regenerative cells (ADRCs) regulated as a device. They have extensive clinical experience using this therapy and are pursuing opportunities in cardiovascular indications, having completed several pilot trials showing safety and potential benefits. Upcoming milestones include publishing long-term cardiovascular trial data, completing a US heart failure trial, progressing their government contract, and achieving revenue targets with additional country approvals of their Celution device.
1) Cytori Therapeutics presented at its 1st Annual Regen Med Investor Day on its cell therapy platform to move technologies from research to clinical use.
2) The platform involves harvesting patient tissue, separating and processing it to produce adipose-derived regenerative cells (ADRCs), and delivering the cells back to the same patient within 1 hour for therapeutic use.
3) Cytori has conducted 43 clinical trials and studies of its cell therapy platform for a variety of applications including soft tissue repair, wounds, ischemia, orthopedics/sports medicine, and vital organs across the USA, EU, Asia Pacific, and Europe/Middle East.
Cytori Therapeutics is a leader in cell therapy focused on improving quality and length of life through innovative cell therapy products. They have developed a point-of-care device called Celution that processes a patient's own fat tissue at the bedside to obtain regenerative adipose-derived stem and regenerative cells (ADRCs). Cytori has an extensive clinical pipeline evaluating ADRCs for cardiovascular, soft tissue, and wound healing applications and has over 50 issued patents related to their cell therapy technologies and applications.
Cytori's presentation discusses its cell therapy platform and pipeline. It provides adipose-derived regenerative cells for cardiovascular disease and breast reconstruction applications. For cardiovascular disease, it is seeking approval in Europe for chronic ischemia and has initiated a US trial. It is also enrolling a pivotal trial in Europe for heart attacks. For breast reconstruction, the Celution system is approved in Europe and aims to gain reimbursement. The presentation highlights the commercial potential and clinical benefits demonstrated for these applications. However, it cautions that the forward-looking statements are subject to risks described in its SEC filings.
Dr. Alex Milstein, VP of Clinical at Cytori presents on the Acute Injury Technology Panel at the Cardiovascular Research Foundation's Conference on Cell Therapy for Cardiovascular Disease on January 25, 2012
Cytori CEO Chris Calhoun presents as part of the "Cardiovascular, AMI & PAD" panel on the Regenerative Medicine Insight Track at the Biotech Showcase on January 10, 2012
This document provides an overview of Cytori Therapeutics' cell therapy technology and clinical trials. Key points include:
- Cytori uses adipose tissue to derive regenerative cells which can be injected to treat cardiovascular and soft tissue conditions. Over 4,000 patients have been treated.
- Clinical trials show potential for treating chronic myocardial ischemia and acute heart attack. The PRECISE trial showed improvements in exercise capacity and infarct size. The APOLLO trial found a 50% reduction in heart damage for cell-treated patients.
- Cytori's goals for 2012 include expanding claims for treating no-option chronic myocardial ischemia in Europe, initiating the ATHENA trial for this in the US
Soft Tissue Repair 18.0
17.0
1. Cytori Therapeutics develops regenerative cell therapy technology using adipose-derived stem cells.
2. Its Celution system processes liposuctioned fat tissue to provide a "cell-enriched graft" containing regenerative cells for soft tissue repair and cardiovascular applications.
3. Clinical trial results show the Celution system is safe and effective for breast reconstruction, with high patient and physician satisfaction rates, supporting reimbursement efforts. A cardiovascular trial also shows improved oxygen uptake post-treatment.
Cytori Cell Therapy aims to improve quality and length of life through innovative cell therapy. The company has treated over 4,000 patients for conditions like cardiovascular disease and soft tissue disorders. Recent clinical trials show promise for treating chronic myocardial ischemia and acute heart attack. For chronic heart failure, cell therapy may help improve heart condition, activity, and reduce mortality for "no option" patients, representing a large potential market.
Digital Banking in the Cloud: How Citizens Bank Unlocked Their MainframePrecisely
Inconsistent user experience and siloed data, high costs, and changing customer expectations – Citizens Bank was experiencing these challenges while it was attempting to deliver a superior digital banking experience for its clients. Its core banking applications run on the mainframe and Citizens was using legacy utilities to get the critical mainframe data to feed customer-facing channels, like call centers, web, and mobile. Ultimately, this led to higher operating costs (MIPS), delayed response times, and longer time to market.
Ever-changing customer expectations demand more modern digital experiences, and the bank needed to find a solution that could provide real-time data to its customer channels with low latency and operating costs. Join this session to learn how Citizens is leveraging Precisely to replicate mainframe data to its customer channels and deliver on their “modern digital bank” experiences.
Dandelion Hashtable: beyond billion requests per second on a commodity serverAntonios Katsarakis
This slide deck presents DLHT, a concurrent in-memory hashtable. Despite efforts to optimize hashtables, that go as far as sacrificing core functionality, state-of-the-art designs still incur multiple memory accesses per request and block request processing in three cases. First, most hashtables block while waiting for data to be retrieved from memory. Second, open-addressing designs, which represent the current state-of-the-art, either cannot free index slots on deletes or must block all requests to do so. Third, index resizes block every request until all objects are copied to the new index. Defying folklore wisdom, DLHT forgoes open-addressing and adopts a fully-featured and memory-aware closed-addressing design based on bounded cache-line-chaining. This design offers lock-free index operations and deletes that free slots instantly, (2) completes most requests with a single memory access, (3) utilizes software prefetching to hide memory latencies, and (4) employs a novel non-blocking and parallel resizing. In a commodity server and a memory-resident workload, DLHT surpasses 1.6B requests per second and provides 3.5x (12x) the throughput of the state-of-the-art closed-addressing (open-addressing) resizable hashtable on Gets (Deletes).
Programming Foundation Models with DSPy - Meetup SlidesZilliz
Prompting language models is hard, while programming language models is easy. In this talk, I will discuss the state-of-the-art framework DSPy for programming foundation models with its powerful optimizers and runtime constraint system.
zkStudyClub - LatticeFold: A Lattice-based Folding Scheme and its Application...Alex Pruden
Folding is a recent technique for building efficient recursive SNARKs. Several elegant folding protocols have been proposed, such as Nova, Supernova, Hypernova, Protostar, and others. However, all of them rely on an additively homomorphic commitment scheme based on discrete log, and are therefore not post-quantum secure. In this work we present LatticeFold, the first lattice-based folding protocol based on the Module SIS problem. This folding protocol naturally leads to an efficient recursive lattice-based SNARK and an efficient PCD scheme. LatticeFold supports folding low-degree relations, such as R1CS, as well as high-degree relations, such as CCS. The key challenge is to construct a secure folding protocol that works with the Ajtai commitment scheme. The difficulty, is ensuring that extracted witnesses are low norm through many rounds of folding. We present a novel technique using the sumcheck protocol to ensure that extracted witnesses are always low norm no matter how many rounds of folding are used. Our evaluation of the final proof system suggests that it is as performant as Hypernova, while providing post-quantum security.
Paper Link: https://eprint.iacr.org/2024/257
GraphRAG for Life Science to increase LLM accuracyTomaz Bratanic
GraphRAG for life science domain, where you retriever information from biomedical knowledge graphs using LLMs to increase the accuracy and performance of generated answers
TrustArc Webinar - 2024 Global Privacy SurveyTrustArc
How does your privacy program stack up against your peers? What challenges are privacy teams tackling and prioritizing in 2024?
In the fifth annual Global Privacy Benchmarks Survey, we asked over 1,800 global privacy professionals and business executives to share their perspectives on the current state of privacy inside and outside of their organizations. This year’s report focused on emerging areas of importance for privacy and compliance professionals, including considerations and implications of Artificial Intelligence (AI) technologies, building brand trust, and different approaches for achieving higher privacy competence scores.
See how organizational priorities and strategic approaches to data security and privacy are evolving around the globe.
This webinar will review:
- The top 10 privacy insights from the fifth annual Global Privacy Benchmarks Survey
- The top challenges for privacy leaders, practitioners, and organizations in 2024
- Key themes to consider in developing and maintaining your privacy program
HCL Notes and Domino License Cost Reduction in the World of DLAUpanagenda
Webinar Recording: https://www.panagenda.com/webinars/hcl-notes-and-domino-license-cost-reduction-in-the-world-of-dlau/
The introduction of DLAU and the CCB & CCX licensing model caused quite a stir in the HCL community. As a Notes and Domino customer, you may have faced challenges with unexpected user counts and license costs. You probably have questions on how this new licensing approach works and how to benefit from it. Most importantly, you likely have budget constraints and want to save money where possible. Don’t worry, we can help with all of this!
We’ll show you how to fix common misconfigurations that cause higher-than-expected user counts, and how to identify accounts which you can deactivate to save money. There are also frequent patterns that can cause unnecessary cost, like using a person document instead of a mail-in for shared mailboxes. We’ll provide examples and solutions for those as well. And naturally we’ll explain the new licensing model.
Join HCL Ambassador Marc Thomas in this webinar with a special guest appearance from Franz Walder. It will give you the tools and know-how to stay on top of what is going on with Domino licensing. You will be able lower your cost through an optimized configuration and keep it low going forward.
These topics will be covered
- Reducing license cost by finding and fixing misconfigurations and superfluous accounts
- How do CCB and CCX licenses really work?
- Understanding the DLAU tool and how to best utilize it
- Tips for common problem areas, like team mailboxes, functional/test users, etc
- Practical examples and best practices to implement right away
For the full video of this presentation, please visit: https://www.edge-ai-vision.com/2024/06/temporal-event-neural-networks-a-more-efficient-alternative-to-the-transformer-a-presentation-from-brainchip/
Chris Jones, Director of Product Management at BrainChip , presents the “Temporal Event Neural Networks: A More Efficient Alternative to the Transformer” tutorial at the May 2024 Embedded Vision Summit.
The expansion of AI services necessitates enhanced computational capabilities on edge devices. Temporal Event Neural Networks (TENNs), developed by BrainChip, represent a novel and highly efficient state-space network. TENNs demonstrate exceptional proficiency in handling multi-dimensional streaming data, facilitating advancements in object detection, action recognition, speech enhancement and language model/sequence generation. Through the utilization of polynomial-based continuous convolutions, TENNs streamline models, expedite training processes and significantly diminish memory requirements, achieving notable reductions of up to 50x in parameters and 5,000x in energy consumption compared to prevailing methodologies like transformers.
Integration with BrainChip’s Akida neuromorphic hardware IP further enhances TENNs’ capabilities, enabling the realization of highly capable, portable and passively cooled edge devices. This presentation delves into the technical innovations underlying TENNs, presents real-world benchmarks, and elucidates how this cutting-edge approach is positioned to revolutionize edge AI across diverse applications.
FREE A4 Cyber Security Awareness Posters-Social Engineering part 3Data Hops
Free A4 downloadable and printable Cyber Security, Social Engineering Safety and security Training Posters . Promote security awareness in the home or workplace. Lock them Out From training providers datahops.com
Your One-Stop Shop for Python Success: Top 10 US Python Development Providersakankshawande
Simplify your search for a reliable Python development partner! This list presents the top 10 trusted US providers offering comprehensive Python development services, ensuring your project's success from conception to completion.
Building Production Ready Search Pipelines with Spark and MilvusZilliz
Spark is the widely used ETL tool for processing, indexing and ingesting data to serving stack for search. Milvus is the production-ready open-source vector database. In this talk we will show how to use Spark to process unstructured data to extract vector representations, and push the vectors to Milvus vector database for search serving.
Salesforce Integration for Bonterra Impact Management (fka Social Solutions A...Jeffrey Haguewood
Sidekick Solutions uses Bonterra Impact Management (fka Social Solutions Apricot) and automation solutions to integrate data for business workflows.
We believe integration and automation are essential to user experience and the promise of efficient work through technology. Automation is the critical ingredient to realizing that full vision. We develop integration products and services for Bonterra Case Management software to support the deployment of automations for a variety of use cases.
This video focuses on integration of Salesforce with Bonterra Impact Management.
Interested in deploying an integration with Salesforce for Bonterra Impact Management? Contact us at sales@sidekicksolutionsllc.com to discuss next steps.
Let's Integrate MuleSoft RPA, COMPOSER, APM with AWS IDP along with Slackshyamraj55
Discover the seamless integration of RPA (Robotic Process Automation), COMPOSER, and APM with AWS IDP enhanced with Slack notifications. Explore how these technologies converge to streamline workflows, optimize performance, and ensure secure access, all while leveraging the power of AWS IDP and real-time communication via Slack notifications.
Have you ever been confused by the myriad of choices offered by AWS for hosting a website or an API?
Lambda, Elastic Beanstalk, Lightsail, Amplify, S3 (and more!) can each host websites + APIs. But which one should we choose?
Which one is cheapest? Which one is fastest? Which one will scale to meet our needs?
Join me in this session as we dive into each AWS hosting service to determine which one is best for your scenario and explain why!
Choosing The Best AWS Service For Your Website + API.pptx
CYTX OneMedForum Investor Talk
1. Cytori, Inc. (Nasdaq: CYTX)
Investor Presentation: OneMedForum
January 11, 2011
Christopher J. Calhoun
Chief Executive Officer
2. Safe Harbor Statement
This presentation may contain certain ‘forward-looking statements’. All statements, other
than statements of historical fact, that address activities, events or developments that
we intend, expect, project, believe or anticipate will or may occur in the future are
forward-looking statements. Such statements are based upon certain assumptions and
assessments made by our management in light of their experience and their perception
of historical trends, current conditions, expected future developments and other factors
they believe to be appropriate.
The forward-looking statements included in this presentation are also subject to a
number of material risks and uncertainties. We caution investors not to place undue
reliance on the forward-looking statements contained in this presentation.
We would advise reading our annual report filed with the United States Securities and
Exchange Commission on Form 10-K for a more detailed description of these risks.
3. Cytori’s Vision: Enable Regenerative Medicine
Medical devices for regenerative medicine
Real-time access to stem and regenerative cells from fatty tissue.
Ischemic conditions: Soft tissue repair, heart disease & others
4. Business Overview
Product Revenue Growth
Razor/razorblade business model
Near-term revenue growth drivers: Approved
and selling products throughout U.S. and ROW
$ Millions
Long-term opportunity: Planned & ongoing trials to
expand Celution labeling for cardiovascular disease
Financial stability
$60 million pro forma cash (end of Q3 2010)
Significant Market Opportunity
Cardiovascular repair: multi-billion worldwide market
Reconstruction/augmentation: $2B + worldwide
Other opportunities to expand Celution labeling
5. Recent Highlights
Revenue Generating Units
Increasing installed-based of Celution® System (Cumulative)
150
Increased 34% year-to-date 135
122
Expanded CE Mark (July ‘10): reconstructive & wounds 110
101
100
85
Reimbursement expected to accelerate sales growth 70
European post-marketing study complete results H1 ‘11 59
50
Initiating approval heart attack trial Q1 2011
Strategic equity agreement with Astellas Q4 2010 0
Q1 Q2 Q3 Q4 Q1 Q2 Q3
$10M including liver partnership right of first refusal
'09 '09 '09 '09 '10 '10 '10
Completed $20 MM secondary offering October 2010
6. Regenerative Medicine Evolution
Treatment Evolution Nothing Devices Drugs Transplants Regenerative Medicine
Embryonic
Regenerative Medicine •Controversial
The process of creating living, functional tissues Cell Therapy
•few patients treated
to repair or replace tissue or organ function lost Introducing new cells into a tissue
to treat a disease •Expensive COGS
due to damage, or congenital defects.
•Donor only
•Biologic dev. path
Adult Stem Cells
(Bone Marrow, Adipose Fat Tissue) Cytori has ONLY medical device
that allows for the extraction
and re-injection of adipose
Adipose tissue-derived stem and
Bone Marrow
•On Market regenerative cells (ADRC)
•Difficult to Access
•path700+ pt treated
•Expensive COGS
•Viable biz. Model
•Donor or autologous
•Donor or autologous
•Biologic dev. path
•Device-based
7. Cytori’s Approach
Process Applications
Cardiovascular Breast Reconstruction
Adipose: rich source
for stem and
regenerative cells
Adipose tissue Additional Indications
Facial Rejuvenation (including radiation injury, urinary
processed at point- incontinence, wound repair)
of-care
Cells available for re-
injection in same
surgical procedure
9. Celution® System
Sale of system
+ Recurring revenue
Single use, per-case cartridge
10. Celution® Cell-Enriched Fat Graft
‘Cell-Enriched
Graft’
Cells Fat $43 $73 $128
$76 $126 $163
Clinical Clinical Clinical
Partner Partner Partner
Hospital-Based Applications Plastic Surgery Clinic Applications
Reconstruction (breast) Breast augmentation
Breast Asymmetry Facial Rejuvenation
Skin and scars Buttock Augmentation
Soft tissue defect repair Augmentation of the chin, lips or cheeks
Wasting of the face and hands
11. Soft Tissue Application: Reconstruction
Celution® Cell-Enriched Fat Graft
European approval July 2010
Hospital-based procedure and call point
Seeking reimbursement
Last-Patient / Last Visit Nov 2010
Complete results H1 2011
Post-marketing RESTORE-2 study
82% physician satisfaction
73% patient satisfaction
Improvement in scar, pigmentation, symmetry and defect index:
+ 2.8 to 3.9 in patient assessment (0-5 scale)
+ 3.1 to 4.1 in physician assessment (0-5 scale)
12. Soft Tissue Application: Aesthetic
Celution® Cell-Enriched Fat Graft
Initial product introduction early 2008 in Europe and Asia Pacific
13. Supplemental Product Line:
PureGraft™: Natural Filler Application
Optimizes preparation of autologous fat graft
Worldwide approval
Complements Celution® in Europe
• Optimizes prep of fat graft
• Celution® lead qualifier
Stand-alone product in US
• Convert users to Celution® upon U.S. clearance
• Point-of-Entry: Building out US sales team (6 direct reps)
Addresses $1.7 billion dermal fill market;
• 46K annual fat- grafting procedures in U.S. and growing
14. Supplemental Product Line:
StemSource Cell & Tissue Bank
Complements plastic surgery practices
• Liposuction customer candidates
• Captures patient retention
• Revenue source
Worldwide product offering
• System
• Cryopreservation chamber tools
• Proprietary protocol, software, database
Distribution network
• GE Healthcare: EU, North America
• Green Hospital Supply (Japan, Thailand, Taiwan, Korea)
Current banking customers in Europe, Japan and U.S.
15. Near-Term Growth Driver: Soft Tissue Repair
Celution product sales: CE Mark designation
• Access to 2/3 worldwide market
• Cosmetic surgery clinics
• Hospitals for breast cancer reconstruction
Celution Consumable Shipments
July 2010: Expanded CE Mark for reconstructive (cumulative)
surgery
• RESTORE-2 final results expected H1 2011
• Intended to support reimbursement efforts
Expanding sales force footprint
• 16 direct sales and marketing worldwide
• Distributors covering select countries in EU and AP
16. Soft Tissue: International Launch & Expansion
Potential System & Consumable Market
Celution® System: in the 27 CE Mark Countries
• Sales team to focus on hospitals
• Emphasis: breast reconstruction
• Focus geographies: UK, Italy, & Germany
• GE Healthcare complements direct sales
• RESTORE 2 post-marketing study 2,000
• Reimbursement
Total Hospitals Total Breast Recon
PureGraft™ Procedures/Year
• Complements Celution® customer’s procedures *Backlog: 2 MM + patients
• Rely on distributors
• Incentivize distributors to generate Celution® leads
19. Long-Term Opportunity: Cardiovascular
Completed Celution® safety and feasibility studies
• Acute myocardial infarction (Heart Attack)
• Chronic myocardial ischemia (severe form of CHF)
Design & Outcomes
• Multi-center, double-blind, placebo-controlled
• Demonstrated safety of injection of Celution-derived
stem and reg. cells
• Strong and consistent efficacy signals in acute and
chronic heart disease
• Improved endpoints are key prognosticators of long-
term outcomes
20. Acute Myocardial Infarction (AMI)
(APOLLO Trial – pilot study)
Meaningful reduction in infarct size
• Entire cohort of patients
o 32% to 15% in treated group
o No change in untreated group
• Matched pair
o 5.1% greater reduction in treated
5.7% improvement in LVEF (SPECT)
3.5 x greater perfusion improvement
21. Cardiovascular: Next Steps
Initiate pivotal AMI Study in Europe (ADVANCE)
• Approx. 350 patients
• Three arms: 20 MM cells, 30 MM cells, & placebo
• Up to 35 centers
• Utilize Celution® One
• To begin Q1 2011
Add other vascular indications:
• Chronic Heart Disease
• Peripheral Vascular Disease
• Others
22. Chronic Heart Disease (CHD)
(PRECISE Trial – pilot study)
MVO2:significant change at 18 months
• MVO2 correlates to improved survival
• MVO2 ≤ 14 = 47%1 yr survival rate
METS: significant change at 18 months
Infarct size: 8.2% change at 6 months
Celution® procedure safe and feasible
through18-months
Lower cardiac mortality rate:
• At avg. follow up of 28 months:
- 2/6 placebo pts died of cardiac causes
- 1/21 treated pts died of cardiac causes
23. Strong R&D Pipeline
Initiate pivotal AMI Study in Europe (ADVANCE)
Investigator-sponsored trials
• SUI
• Liver
• Renal
• Malignant wounds
• Cardiomyopathy
• Vocal cord paralysis
• HIV therapy-induced soft tissue atrophy
• Others
Celution® One: Next-generation product
• Available for ADVANCE heart attack trial
• Manufacturing expertise
• Service infrastructure
• Committed Partner: invested $55+mm
24. Balance Sheet Highlights
Cash: $60 million pro forma (less Q4 2010 burn)
• Cash (9/30/10): $30.7 M
• Equity Raise (Oct. 10): $19.3 M
• Strategic Equity (Dec. 10): $10 M investment from Astellas Pharma
Long-term Debt: $20 million (GE/SVB/Oxford term loan)
Shares Outstanding: 52 million as adjusted
25. Key Takeaways
Providing solutions for the “Future” of medicine “Today”
Near-term system and consumable revenue growth driven by soft tissue
Recent approvals, expanded indications, and pursuing reimbursement
Enormous opportunity in ischemic conditions
Strong partners/investors: GE Healthcare, Olympus, Green Hospital, Astellas
Strong balance sheet
Cytori is medical device company that is providing surgeons and hospitals with the tools they need to practice regenerative medicine. Core product is the Celution® System We’re unique in the stem cell field because we’re focused entirely on giving patients access to stem and regenerative cells, which reside naturally in their own fat tissue Our vision is to ultimately have at least one of the systems you see pictured installed in every hospital and clinic around the globe.
Commercial model is based on the highly profitable razor-razorblade Increasing our installed base and driving consumable usage in the soft tissue area Building for the long-term through clinical trials to bring cardiac indications to market We’ve strengthened the balance sheet last quarter to support this growth Take away: Selling regenerative medicine products today into a large aesthetics and reconstructive market and building to tomorrow to penetrate an even larger cardiac market
Before we dive into the presentation, let me give you an idea of some recent highlights We continue to penetrate the market, having now placed 135 revenue generating Celution devices into the marketplace Our consumables have grown 34% year to date, and we expect the ability to significantly increase that rate to occur due to a couple of near term catalysts: First, we have recently received expanded CE mark to add reconstructive procedures to the label and are in the process to see reimbursement soon Simultaneously, we are initiating a pivotal study in Europe, ADVANCE, for heart attach approval We have seen strong support from both the business development community with a recent strategic equity agreement from the XXth largest pharma company in the world as well as a non-warrant equity markets transaction
Regenerative Medicine, what does it really mean when we talk about treated patients with stem cells? **Chris or Mark H. apply appropriate language***
While many stem cell companies talk about the future of medicine and how the anticipate treating patients, we are actually doing it. We have treated X thousand patients over the last X years, which is just the beginning.
As we discussed, we operate in a razor / razorblade model. The Celution system currently sells for $100K, while the consumables sell for $2500. We anticipate the sales price to ***increase to $5,000??***
The Celution system is originally being marketed to 2 areas of regenerative medicine: reconstructive and aesthetic. The distinction of these two areas is in the location of the procedure and the general reimbursement of the procedure.
In the reconstructive market, the focus is on breast reconstruction following XX. Data suggests XXX compared to XX for alternatives.
Sales heretofore have focused on aesthetic applications Injected tissue retains value over time, allowing cell-enriched grafts to be applied toward augmentation, facial, etc.
Supplementing our Celution system, we have designed and developed PureGraft. PureGraft optimizes preparation of autologous fat graft. We see PureGraft as a complement to Celution in Europe and as a stand alone product in the US. Not only does PureGraft address the $1.7 billion dermal fill market, but it acts as lead qualifier for Celution
Select hospitals are conducting their own independent investigator initiated studies. These studies hold the potential to expand and identify new applications for Celution. Cytori offers its Celution device, along with laboratory equipment to academic centers interested in conducting clinical and preclinical work. In North America, the system is distributed by GE Healthcare, and in Asia Pacific, it is distributed by our agreement with Green Hospital Supply.
The Celution device is originally being marketed to X,XXX hospitals throughout much of the world. We have just received CE mark expansion into the reconstructive market and anticipate reimbursement soon. This is expected to be a significant catalyst to the further penetration of the marketplace. To prepare, we are significantly expanding our sales footprint. We have initially brought on XX direct sales and marketing personnel, and have lined up XX distributors to address XX countries. We are also looking for additional label expansion with ongoing clinical trials.
Sales team will focus their efforts on calling on hospitals, due to the newly expanded indications of breast reconstruction and chronic wounds Taking the UK alone, there are 250 potential hospital customers for Celution who are already performing 1200 reconstructive surgery procedures per year, which could utilize our consumables. PureGraft, which was recently launched in Europe will be sold more through distributors. It can be used on its own or in combination with Celution. It’s an ideal entry point into the plastic surgeon’s office, with a lower price, and higher volume users will naturally become leads for upselling Celution®
We have seen consistent growth in revenues without any significant labeling. With the recent CE mark expansion to include reconstructive surgery, we believe there is significant near-term opportunities to increases revenues. Long-term, as we continue to place units worldwide, the ability to expand labels and approvals will increase not only the installed base, but the number of consumable used per day, or per week.